107 related articles for article (PubMed ID: 3963858)
1. [The clinical value of long-term administration of OK-432 in head and neck cancer].
Mitarai K; Tsukuda M; Tamamushi N; Mochimastu I; Kubota A; Sawaki S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):945-50. PubMed ID: 3963858
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
[TBL] [Abstract][Full Text] [Related]
3. [Role of immune skin reactions in progressive lung cancer during the administration of OK-432--relation to reactions to DNCB, PPD and Su-PS].
Katada H; Nishikawa K; Yoneda T; Kitamura H; Nakajima A; Mikami R
Gan To Kagaku Ryoho; 1987 Jan; 14(1):61-70. PubMed ID: 3026256
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
Horiuchi M; Sato K; Nakarai I; Shinoda A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
Kikkawa N; Sasai H; Kawahara T
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients].
Yagi Y; Yagi S; Ichiki H
Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on the effect of adjuvant immunochemotherapy using OK-432 and 5-FU in pharyngeal and laryngeal cancers].
Yajin K; Harada Y; Tagashira N; Suzuki M; Hirakawa K; Sera K; Nakata M; Takebayashi S; Okazaki H; Yashiki T
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1921-7. PubMed ID: 3289502
[TBL] [Abstract][Full Text] [Related]
8. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432].
Nakarai I; Rikitake H; Koga T; Hayashi A; Harada Y; Takamoto M; Ishibashi T; Shinoda A; Sagawa K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723
[TBL] [Abstract][Full Text] [Related]
9. Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment.
Yoshimura Y; Oka M; Harada T; Inou Y; Saito H; Odagawa T; Matsumoto K
J Osaka Univ Dent Sch; 1989 Dec; 29():117-22. PubMed ID: 2577382
[TBL] [Abstract][Full Text] [Related]
10. [Study on adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
Kikkawa N; Kawahara T
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1881-5. PubMed ID: 3382240
[TBL] [Abstract][Full Text] [Related]
11. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of various administration routes of the streptococcal preparation, OK-432, with regard to their in vivo effect by lymphocytes proliferation assay].
Kimura Y; Toki H; Okabe K; Fujii M; Tamai M
Gan To Kagaku Ryoho; 1986 Jan; 13(1):95-100. PubMed ID: 3942400
[TBL] [Abstract][Full Text] [Related]
13. [Clinical investigation of intratumoral OK-432 administration].
Shimada K; Tabuse K; Kono N; Katsumi M; Yamamoto H; Yamamoto Y; Endo A
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1844-9. PubMed ID: 6882008
[TBL] [Abstract][Full Text] [Related]
14. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770
[TBL] [Abstract][Full Text] [Related]
15. [The alternation of peripheral lymphocyte subsets in head and neck carcinoma].
Mitarai K; Tsukuda M; Mochimatsu I; Kubota A; Sawaki S
Gan No Rinsho; 1986 Jul; 32(8):849-54. PubMed ID: 3747146
[TBL] [Abstract][Full Text] [Related]
16. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
Miyamoto Y; Takeshita M; Izuo M
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3229-35. PubMed ID: 3777960
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies of long-term administration of OK-432 in patients with gynecologic cancer].
Mano T; Kawamoto K; Miyake T; Torigoe T
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1439-45. PubMed ID: 2685142
[TBL] [Abstract][Full Text] [Related]
19. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
20. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.
Kimura T; Suzuki K; Motai H; Miyamoto N; Tsuge I; Ito Y; Baba S
Acta Otolaryngol Suppl; 1996; 525():135-41. PubMed ID: 8908288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
